AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
Today, ActiveWallSt.com is promoting its technical alert briefings. Get all of our alerts free by signing up to http://www.activewallst.com/.
Despite pressures in pricing and competition, the Drug Manufacturers industry continues to present opportunities to many investors. Let us see how investors see some of the big names within this space. Find out how you can benefit from these stocks’ technical alerts at:
Let us see how these equities performed at their last close on Friday, May 20, 2016:
Novo Nordisk A/S (NYSE: NVO)
Shares in healthcare company, Novo Nordisk A/S, gained 0.41%, finishing the trading session at $53.92 with a total volume of 1.01 million shares traded. The stock has advanced 6.35% over the previous three months. The Company’s shares are trading below their 200-day moving averages by 0.54%. Additionally, Novo Nordisk’s stock has a Relative Strength Index (RSI) of 44.11.
Biodel Inc. (NASDAQ: BIOD)
Shares of specialty biopharmaceutical company, Biodel Inc., ended the session at $0.39, gaining 1.59%. The stock recorded a trading volume of 1.05 million shares. The Company’s shares have advanced 18.18% in the previous three months and 14.71% on an YTD basis. The stock is trading 4.31% above its 50-day moving average. Moreover, shares of Biodel have an RSI of 53.05.
Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP)
On Friday, shares in Sucampo Pharmaceuticals Inc. recorded a trading volume of 305,273 shares. The stock edged 4.04% higher, closing the day at $11.59. The Company’s shares are trading 5.82% above their 50-day moving average. Additionally, Sucampo Pharmaceuticals’ stock has an RSI of 60.80.
SciClone Pharmaceuticals Inc. (NASDAQ: SCLN)
SciClone Pharmaceuticals Inc. is a specialty pharmaceutical company that offers therapies for oncology, infectious diseases, and cardiovascular disorders in China, the U.S., and Hong Kong. Shares of the Company recorded a trading volume of 348,034 shares on Friday. The stock ended the session at $12.54, gaining 0.48%. The Company’s shares have advanced 36.75% in the previous three months and 36.30% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.41% and 36.49%, respectively. Furthermore, shares of SciClone Pharma have an RSI of 53.95. Technical alert on SCLN is available for free at:
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.activewallst.com.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: ActiveWallStreet.com
ReleaseID: 440294
Copyright © 1999-2013 SproutNews.com
